| Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013 | 623 | 2013 |
| Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin … A Dueñas-González, JJ Zarbá, F Patel, JC Alcedo, S Beslija, L Casanova, ... Journal of Clinical Oncology 29 (13), 1678-1685, 2011 | 529 | 2011 |
| Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors A Duenas-Gonzalez, M Candelaria, C Perez-Plascencia, ... Cancer treatment reviews 34 (3), 206-222, 2008 | 422 | 2008 |
| Epigenetics of cervical cancer. An overview and therapeutic perspectives A Dueñas-González, M Lizano, M Candelaria, L Cetina, C Arce, ... Molecular cancer 4, 1-24, 2005 | 299 | 2005 |
| A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors M Candelaria, D Gallardo-Rincón, C Arce, L Cetina, JL Aguilar-Ponce, ... Annals of Oncology 18 (9), 1529-1538, 2007 | 296 | 2007 |
| Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy B Segura-Pacheco, C Trejo-Becerril, E Perez-Cardenas, L Taja-Chayeb, ... Clinical Cancer Research 9 (5), 1596-1603, 2003 | 295 | 2003 |
| OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line–specific manner AD Gonzalez, M Kaya, W Shi, H Song, JR Testa, LZ Penn, J Filmus The Journal of cell biology 141 (6), 1407-1414, 1998 | 244 | 1998 |
| The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug M Juarez, A Schcolnik-Cabrera, A Dueñas-Gonzalez American journal of cancer research 8 (2), 317, 2018 | 228 | 2018 |
| Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline LT Chuang, S Temin, R Camacho, A Dueñas-Gonzalez, S Feldman, ... Journal of global oncology 2 (5), 311-340, 2016 | 221 | 2016 |
| Ether a go-go potassium channels as human cervical cancer markers LMB Farias, DB Ocana, L Diaz, F Larrea, E Avila-Chávez, A Cadena, ... Cancer research 64 (19), 6996-7001, 2004 | 205 | 2004 |
| A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative … RE Kast, JA Boockvar, A Brüning, F Cappello, WW Chang, B Cvek, ... Oncotarget 4 (4), 502, 2013 | 201 | 2013 |
| A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes P Zambrano, B Segura-Pacheco, E Perez-Cardenas, L Cetina, ... BMC cancer 5, 1-12, 2005 | 201 | 2005 |
| Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer A Serrano-Olvera, A Dueñas-González, D Gallardo-Rincón, M Candelaria, ... Cancer treatment reviews 32 (3), 180-190, 2006 | 177 | 2006 |
| A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin … A Duenas-Gonzalez, C Lopez-Graniel, A Gonzalez-Enciso, L Cetina, ... Annals of oncology 14 (8), 1278-1284, 2003 | 173 | 2003 |
| A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer C Arce, C Pérez-Plasencia, A González-Fierro, E de la Cruz-Hernández, ... PloS one 1 (1), e98, 2006 | 171 | 2006 |
| Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study A Chavez-Blanco, B Segura-Pacheco, E Perez-Cardenas, L Taja-Chayeb, ... Molecular cancer 4, 1-9, 2005 | 170 | 2005 |
| Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines A Chavez-Blanco, C Perez-Plasencia, E Perez-Cardenas, ... Cancer cell international 6, 1-9, 2006 | 163 | 2006 |
| A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results J Coronel, L Cetina, I Pacheco, C Trejo-Becerril, A González-Fierro, ... Medical oncology 28, 540-546, 2011 | 159 | 2011 |
| Modern management of locally advanced cervical carcinoma A Dueñas-Gonzalez, L Cetina, I Mariscal, J de la Garza Cancer treatment reviews 29 (5), 389-399, 2003 | 159 | 2003 |
| Cancer progression mediated by horizontal gene transfer in an in vivo model C Trejo-Becerril, E Pérez-Cárdenas, L Taja-Chayeb, P Anker, ... PloS one 7 (12), e52754, 2012 | 157 | 2012 |
